Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16934255 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL16933756 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL45608 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL16933803 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12672703 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL16933950 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1894988 | 1.00 | — | — | |
| SCHEMBL5813108 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL16933741 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 | |
| SCHEMBL28664163 | 1.00 | CA12 (0.33) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1121410-C | Process for preparation of N-methyl-D-phenylalanyl-N-[1-[3-[(aminoiminomethyl)-amino] propyl]-3,3-difluoro-2-oxohexyl]-L-prolinamide | AVENTIS MEDICINE CO (US) | 2003-09-17 | — | — | CN | claimed |
| EP-1012165-A1 | PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N- 1- 3- (AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE | Aventis Pharmaceuticals Inc. (US) | 2000-06-28 | — | — | EP | claimed |
| CN-1214691-A | Process for preparation of N-methyl-D-phenylalanyl-N-[1-[3-[(aminoiminomethyl)-amino] propyl]-3,3-difluoro-2-oxohexyl]-L-prolinamide | HOECHST MARION ROUSSEL INC (US) | 1999-04-21 | — | — | CN | claimed |
| WO-1997035874-A1 | PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N-[1-[3-[(AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-02 | — | — | WO | claimed |
| EP-3527600-B1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-119219824-A | Crosslinked polymer and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119219840-A | Crosslinked polymer and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-116063345-B | Phosphonic acid group monomer and preparation method thereof | 中国石油化工股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-116063626-B | Anti-calcium shrinkage and expansion agent and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-116064016-B | Scale inhibition anti-swelling shrinkage swelling agent and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116064016-A | Scale inhibition anti-swelling shrinkage swelling agent and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063345-A | Phosphonic acid group monomer and preparation method thereof | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20170298169-A1 | Polyisocyanate Composition and Isocyanate Polymer Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-2915803-A1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | Asahi Kasei Chemicals Corporation (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150210631-A1 | Polyisocyanate Composition and Isocyanate Polymer Composition | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| CN-1121410-C | Process for preparation of N-methyl-D-phenylalanyl-N-[1-[3-[(aminoiminomethyl)-amino] propyl]-3,3-difluoro-2-oxohexyl]-L-prolinamide | AVENTIS MEDICINE CO (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1012165-A1 | PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N- 1- 3- (AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE | Aventis Pharmaceuticals Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| CN-1214691-A | Process for preparation of N-methyl-D-phenylalanyl-N-[1-[3-[(aminoiminomethyl)-amino] propyl]-3,3-difluoro-2-oxohexyl]-L-prolinamide | HOECHST MARION ROUSSEL INC (US) | 1999-04-21 | — | — | CN | disclosed |
| WO-1997035874-A1 | PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N-[1-[3-[(AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5396022-A | Defluorination of alkane streams | PHILLIPS PETROLEUM COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298169-A1 | Polyisocyanate Composition and Isocyanate Polymer Composition | TST, SUDS3, SCLY | CA12 1565/4885CA1 1160/4885CA2 1710/4885 |
| US-20150210631-A1 | Polyisocyanate Composition and Isocyanate Polymer Composition | TST, SUDS3, SCLY | CA12 1565/4885CA1 1160/4885CA2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.